EYA4, a member of the EYA family, has been identified as a promising tumor suppressor in HCC, potentially inhibiting malignant behaviors in HCC cell lines by interfering with NF-κB/RAP1 signaling activation [145]. Here, NFKB1 is linked to hepatocellular carcinoma.